5439-13-4

Basic information

• Product Name: 2-BROMO-N-(4-BROMOPHENYL)ACETAMIDE
• Synonyms: 2-BROMO-N-(4-BROMOPHENYL)ACETAMIDE;acetamide, 2-bromo-N-(4-bromophenyl)-;Nsc15062;2-bromo-N-(4-bromophenyl)ethanamide;Acetamide, N-(4-bromophenyl)-2-bromo-
• CAS NO: 5439-13-4
• Molecular Formula: C₈H₇Br₂NO
• Molecular Weight: 292.96
• Mol File: 5439-13-4.mol
• Article Data: 23

Chemical Properties

• Boiling Point: 398.5°C at 760 mmHg
• Flash Point: 194.8°C
• Appearance: /
• Density: 1.928g/cm³
• Vapor Pressure: 1.47E-06mmHg at 25°C
• Refractive Index: 1.658
• CAS DataBase Reference: 2-BROMO-N-(4-BROMOPHENYL)ACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-N-(4-BROMOPHENYL)ACETAMIDE(5439-13-4)
• EPA Substance Registry System: 2-BROMO-N-(4-BROMOPHENYL)ACETAMIDE(5439-13-4)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 5439-13-4(Hazardous Substances Data)

Usage

General Description

2-BROMO-N-(4-BROMOPHENYL)ACETAMIDE is a chemical compound with the molecular formula C8H8Br2NO. It is a brominated derivative of acetamide, with a bromine atom attached to the nitrogen and another to the phenyl group. 2-BROMO-N-(4-BROMOPHENYL)ACETAMIDE has potential applications in organic synthesis and pharmaceutical research, as it can be used as a building block for the synthesis of various other compounds. It may also have biological activity and could be used as a starting point for the development of new drugs or agrochemicals. However, as with any chemical, it should be handled and used with care, following proper safety protocols and under the guidance of trained professionals.

InChI:InChI=1/C8H7Br2NO/c9-5-8(12)11-7-3-1-6(10)2-4-7/h1-4H,5H2,(H,11,12)

Upstream product

• 22118-09-8 2-bromoacetyl chloride 
• 106-40-1 4-bromo-aniline 
• 5326-87-4 N-(phenyl)bromoacetamide 
• 598-21-0 2-Bromoacetyl bromide 

Downstream Products

• 6096-73-7 {[(4-Bromo-phenylcarbamoyl)-methyl]-methoxycarbonylmethyl-amino}-acetic acid methyl ester 
• 5502-60-3 N-<4-Brom-acetanilido>-iminodiessigsaeure 
• 742085-52-5 N-(4'-chloro-1,1'-biphenyl-4-yl)-2-[2-methoxy-4-(1-pyrrolidinylmethyl)phenoxy]acetamide 
• 742085-59-2 C₁₆H₁₄BrNO₃ 
• 1019400-82-8 1-[(4-bromo-phenylcarbamoyl)-methyl]-5-methyl-1H-pyrazole-3-carboxylic acid ethyl ester 
• 1019399-83-7 C₁₅H₁₆BrN₃O₃ 
• 1207456-43-6 C₁₈H₁₃BrN₄OS 
• 1009450-70-7 N-(4-bromophenyl)-2-(2-(thiazol-4-yl)-1H-benzo[d]imidazol-1-yl)acetamide 
• 1370556-88-9 N-(4-bromophenyl)diethylphosphonoacetamide 
• 89473-80-3 N-(4-bromophenyl)-2-morpholinoacetamide 
• 1365999-73-0 2-morpholino-N-(4-(pyridin-3-yl)phenyl)acetamide 
• 1426560-69-1 C₄₅H₃₆N₆OPt 
• 1426560-71-5 2-(bis(pyridin-2-ylmethyl)amino)-N-(4-((trimethylsilyl)ethynyl)phenyl)acetamide 
• 1426560-72-6 2-(bis(pyridin-2-ylmethyl)amino)-N-(4-ethynylphenyl)acetamide 

Relevant articles and documents

Design, synthesis, in vitro antiproliferative evaluation and in silico studies of new VEGFR-2 inhibitors based on 4-piperazinylquinolin-2(1H)-one scaffold

Angiogenesis is essential in the growth of solid tumors which need oxygen and nutrients supply to grow in size. The VEGF/VEGFR-2 signaling pathway plays an important role in tumor angiogenesis. Sorafenib is an FDA approved cancer therapeutic with activity

Selective carbonic anhydrase inhibitor, synthesis method and application thereof

The invention discloses a selective carbonic anhydrase inhibitor. The compound adopts acetazolamide as a lead compound, and is designed and synthesized by introducing a side chain for structural modification. The structure comprises a monosubstituted compound and a disubstituted compound; the selective inhibition effect of the compound on carbonic anhydrase is evaluated by esterase method; the neuroprotective effect of the compound is evaluated through a sodium nitroprusside oxidative stress model; and the toxicity of the compound is tested through cytotoxicity experiment. Research results show that in terms of the inhibition effect of the compound on carbonic anhydrase, monosubstitution is superior to disubstitution; the selectivity to carbonic anhydrase II is superior to that of carbonicanhydrase IX; the monosubstituted compound presents certain protective effect on sodium nitroprusside damaged PC12 cells; the IC50 of the optimal compound to carbonic anhydrase II is 16.7nM, the IC50to carbonic anhydrase IX is 4757nM, the selectivity is 285 times, which is remarkably superior to that of acetazolamide; the neuroprotective effect on PC12 is close to that of acetazolamide, and thetoxicity is lower than that of acetazolamide. The compound has the characteristics of good selectivity, effectiveness and safety, and is expected to be applied to drugs for preventing and treating neurological diseases.

Design, synthesis of novel (Z)-2-(3-(4-((3-benzyl-2,4-dioxothiazolidin-5-ylidene)methyl)-1-phenyl-1H-pyrazol-3-yl)phenoxy)-N-arylacetamide derivatives: Evaluation of cytotoxic activity and molecular docking studies

In an attempt to discover potential cytotoxic agents, a series of novel (Z)-2-(3-(4-((3-benzyl-2,4-dioxothiazolidin-5-ylidene)methyl)-1-phenyl-1H-pyrazol-3-yl) phenoxy)-N-arylacetamide derivatives 11a-n were synthesized in varied steps with acceptable reaction procedures with good yields and characterized by 1H NMR, 13C NMR, IR and ESI-MS spectra. All the novel synthesized derivatives were assessed for their cytotoxic activity against human breast cell line (MCF-7) with different concentration of 0.625 μM, 1.25 μM, 2.5 μM, 5 μM and 10 μM respectively. Biological evaluation assay results were displayed in terms of percentage of cell viability reduction and IC50 values. Most of the screened derivatives demonstrated moderate to promising cytotoxic activity. Some of the derivatives, particularly compound 11d and 11n have shown promising cytotoxic activity with IC50 values 0.604 μM and 0.665 μM compared to standard drug cisplatin and compounds 11a, 11e and 11g also have shown considerable cytotoxic activity and the rest of the derivatives have shown moderate activity. Furthermore, molecular docking calculations and ADME properties of the synthesized molecules are in effective compliance with the cytotoxic evaluation results.